Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-09-04
2007-09-04
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S200100, C530S388220, C536S023530
Reexamination Certificate
active
10977369
ABSTRACT:
The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity.
REFERENCES:
patent: 6569430 (2003-05-01), Waldmann et al.
patent: 6982321 (2006-01-01), Winter
patent: 2003/0153043 (2003-08-01), Carr et al.
patent: 2003/0157641 (2003-08-01), Reff et al.
patent: 2004/0180386 (2004-09-01), Carr et al.
patent: WO92/01059 (1992-01-01), None
patent: WO93/10817 (1993-06-01), None
patent: WO98/52976 (1998-11-01), None
patent: WO98/59244 (1998-12-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 02/30460 (2002-04-01), None
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 1979-1983).
Reichmann et al. (Nature 332:323-327 1988).
Sequence search results for SEQ ID Nos.: 1 (pp. 1-5) and 2 (pp. 1-5).
VH and VL domain map for SEQ ID Nos.: 1 and 2 (1 page).
Asano et al. (J Biochem (Tokyo). Dec. 2002;132(6):903-9).
Takeda et al. (Hybridoma. Feb. 1995;14(1):9-18).
Cheung et al. (J Virol. Nov. 1992;66(11):6714-20).
Cobbold et al., “A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants,”J. Immunol Methods, 127:19-24, 1990.
Dyer, “Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype,”Blood, 73:1431-1439, 1989.
Friend et al., “Reversal of allograft rejection using the monoclonal antibody, campath-1G,”Transplant. Proc, 23:2253-2254, 1991.
Hale et al., “Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection,”Blood, 92:4581-4590, 1998.
Hale et al., “Removal of t cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement,”Blood, 62:873-882, 1983.
Riechmann et al., “Reshaping human antibodies for therapy,”Nature, 332:323-327, 1988.
Schnitzer et al., “Subcutaneous administration of campath-1h: clinical and biological outcomes,”J. Rheumatol, 24:1031-1036, 1997.
Weinblatt et al., “CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis,”Arthritis Rheum, 38:1589-1594, 1995.
Dyer, “The Role of CAMPATH-I Antibodies in the Treatment of Lymphoid Malignancies,”Seminars in Oncology, 26:52-57, 1999.
Carr Francis J.
Hamilton Anita A.
Biovation Ltd.
Bristol Lynn
Fulbright & Jaworski L.L.P.
Helms Larry R.
LandOfFree
Modified anti-CD52 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified anti-CD52 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified anti-CD52 antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3798224